NCT06964763

Brief Summary

Pilonidal sinus disease is a chronic acquired disease leading to significant morbidity and healthcare costs in young man and women. Despite different treatment methods, the disease relatively often leads to postoperative complications and recurrence.(8). Advantages of mini-invasive techniques include: quicker recovery and earlier return to work and high patient satisfaction. Randomized studies are rare and this applies especially to newer mini-invasive techniques. The purpose of the investigators prospective study is to randomly compare the mini-invasive laser ablation technique to the mini-invasive fibrin glue treatment in pilonidal sinus disease surgery.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
188

participants targeted

Target at P75+ for not_applicable

Timeline
44mo left

Started Sep 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Sep 2023Dec 2029

Study Start

First participant enrolled

September 1, 2023

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

April 23, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

May 9, 2025

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 17, 2029

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 17, 2029

Last Updated

May 9, 2025

Status Verified

April 1, 2025

Enrollment Period

5.8 years

First QC Date

April 23, 2025

Last Update Submit

April 30, 2025

Conditions

Keywords

pilonidal sinus diseaselaser ablationfibrine gluerandomized trialprospective study

Outcome Measures

Primary Outcomes (2)

  • Healing rate

    Healing rate will be assessed by a questionnaire and a phone call

    2 months after surgery

  • Quality of life

    Quality of life will be assessed by a questionnaire, the RAND 36-Item Health Survey

    2 months after surgery

Secondary Outcomes (5)

  • Recurrence rate

    1, 3 and 5 years after surgery

  • Cost analysis

    At 2 months after surgery

  • Postoperative complications

    2 - 3 months after the surgery

  • Sick leave

    2 months and 1 year after surgery

  • Recovery time

    2 months and 1 year after surgery

Study Arms (2)

study group 1

ACTIVE COMPARATOR

surgery + laser ablation

Procedure: surgery + laser

study group 2

ACTIVE COMPARATOR

surgery + fibrine glue

Procedure: surgery + fibrine glue

Interventions

laser

study group 1

fibrine glue

study group 2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • primary pilonidal sinus disease
  • age 18 and above

You may not qualify if:

  • recurrent pilonidal sinus disease
  • age under 18
  • inability to understand Finnish or Swedish (the questionnaires are in Finnish and Swedish only, the two official languages of Finland)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HUS Vatsakeskus Abdominal Center of Helsinki University Hospital

Helsinki, Finland

Location

MeSH Terms

Interventions

Laser TherapySurgical Procedures, Operative

Intervention Hierarchy (Ancestors)

TherapeuticsAblation Techniques

Study Officials

  • Pauli Puolakkainen, Professor

    University of Helsinki, Department of Surgery

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 23, 2025

First Posted

May 9, 2025

Study Start

September 1, 2023

Primary Completion (Estimated)

June 17, 2029

Study Completion (Estimated)

December 17, 2029

Last Updated

May 9, 2025

Record last verified: 2025-04

Locations